What the FDA labels say about taking them together
Mycophenolate mofetil and mycophenolic acid
Mycophenolate mofetil's FDA label of August 5, 2026 names mycophenolic acid in its contraindications section, and mycophenolic acid's label names mycophenolate mofetil too. The mycophenolate mofetil label: “Medications on Mycophenolic Acid Concentrations A variety of drugs have potential to alter systemic MPA exposure when co-administered with CELLCEPT.”
Check it at the source: the mycophenolate mofetil FDA label on DailyMed (effective August 5, 2026, Genentech, Inc.); the mycophenolic acid FDA label on DailyMed (effective July 29, 2026, Novartis Pharmaceuticals Corporation).
What does the mycophenolate mofetil label say about mycophenolic acid?
Mycophenolate mofetil label, contraindicationsCONTRAINDICATIONS CELLCEPT is contraindicated in patients with a history of hypersensitivity, including anaphylaxis, to mycophenolate mofetil (MMF), mycophenolic acid (MPA) or any component of the drug product [see Warnings and Precautions (5.8) ].
Mycophenolate mofetil label, drug interactionsDrugs on CELLCEPT Table 7 Drug Interactions with CELLCEPT that Affect Mycophenolic Acid (MPA) Exposure Antacids with Magnesium or Aluminum Hydroxide Clinical Impact Concomitant use with an antacid containing magnesium or aluminum hydroxide decreases MPA systemic exposure [see Clinical Pharmacology (12.3) ], which may reduce CELLCEPT efficacy. Prevention or Management Administer magnesium or aluminum hydroxide containing antacids at least 2h after CELLCEPT administration.
Mycophenolate mofetil label, warnings and precautionsMedications on Mycophenolic Acid Concentrations A variety of drugs have potential to alter systemic MPA exposure when co-administered with CELLCEPT.
Source: FDA drug label (Myhibbin, NDA216482), Azurity Pharmaceuticals, Inc., effective April 1, 2026 (SPL set d9af72d6-7b3e-4c08-94b9-1d8b499cb7f9), via openFDA
Source: FDA drug label (CellCept), NDA050722 (Roche Palo), as published by Genentech, Inc., effective August 5, 2026 (SPL set 37241e87-4af4-4dc3-a1aa-ea6f20d8dc40), via openFDA; the full label on DailyMed
What does the mycophenolic acid label say about mycophenolate mofetil?
Mycophenolic acid label, contraindicationsCONTRAINDICATIONS Myfortic is contraindicated in patients with a history of hypersensitivity, including anaphylaxis, to mycophenolate sodium, mycophenolic acid (MPA), mycophenolate mofetil, or to any of its excipients [see Warnings and Precautions (5.9), Adverse Reactions (6.2)].
Source: FDA drug label (Myfortic), Novartis Pharmaceuticals Corporation, effective July 29, 2026 (SPL set eed26501-890d-4ff6-88e7-6dbea4726e53), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Mycophenolate mofetil | Mycophenolic acid | |
|---|---|---|
| Labeled for | Organ transplant rejection | Organ transplant rejection |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.138 per capsule 250 mg capsule | $0.0996 per tablet 180 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once